Blood fibroblast growth factor 23 concentration in cats with and without chronic kidney disease: a scoping review

Abstract

Objectives This study undertook a scoping review of research on blood fibroblast growth factor 23 (FGF-23) concentrations in healthy non-azotemic cats and cats with chronic kidney disease (CKD) to describe the volume and nature of existing literature, to determine whether published studies provide adequate evidence to support the use of FGF-23 as a biomarker in clinical practice and to identify any existing gaps in knowledge. Methods PRISMA Extension for Scoping Reviews guidelines were used to design and perform the scoping review. Online databases were used to identify observational and clinical studies of blood FGF-23 concentrations in healthy cats and cats with CKD published before December 2022. Study and population characteristics and descriptive data on FGF-23 concentrations were extracted. Results A total of 205 publications were reviewed; 17 were retained for inclusion. Most studies were retrospective. Most studies included cats with International Renal Interest Society stage 2–4 CKD, with some variation. Key concepts explored in the literature include FGF-23 concentrations by CKD stage, effect of dietary phosphate restriction on FGF-23 concentrations, relationship between FGF-23 concentrations and blood phosphorus, calcium and magnesium concentrations, and FGF-23 concentrations in cats with progressive CKD. FGF-23 concentrations tended to be higher in cats with CKD compared with healthy cats, with an overlap between healthy and CKD populations, and there was significant variation within stages of CKD. Conclusions and relevance FGF-23 is a biomarker of interest for the management and monitoring of phosphate overload in cats. Studies support several potential clinical applications for measuring FGF-23 concentration in practice; however, evidence is limited. Research on FGF-23 in cats with CKD would benefit from longitudinal, prospective studies that standardize CKD diagnosis and categorize cats by stage using current guidelines. Studies should include cats with early-stage, non-azotemic CKD and use commercially available assays so such results are comparable across studies.

Establishing a Reference Interval for Fibroblast Growth Factor (FGF)-23 in Cats

“…The general guidelines of the laboratory recommend taking blood samples after overnight fasting to exclude the influence of feeding, especially on biochemistry parameters. FGF-23 is a useful biomarker for identification and better understanding of CKDmineral and bone disorder [30]. Further studies in cats are needed to evaluate the outcome of an early dietary invention in cats with increased FGF-23 levels.…”

“…FGF-23 is a useful biomarker for the identification and better understanding of CKD–mineral and bone disorder [ 30 ]. Further studies in cats are needed to evaluate the outcome of an early dietary invention in cats with increased FGF-23 levels.…”

“…Further studies in cats are needed to evaluate the outcome of an early dietary invention in cats with increased FGF-23 levels. The value of FGF-23 in the identification and prediction of CKD progression has to be further evaluated [ 30 ].…”